Synthetic inhibitors of coagulation factor Xa

Bibliography

• RHONE-POULENC RORER: Lovenox is the first prescrip-tion drug approved by FDA for unstable angina and non-Q-wave myocardial infarction. Company Press Re-lease (30 March, 1998).
   Google Scholar
• VUILLEMENOT A, SCHIELE F, MENEVEAU N et al.: Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibi-tor, as an antithrombotic agent - a pilot study in the set-ting of coronary angioplasty. Thromb. Haemost. (1999) 81:214–220.
   PubMed Web of Science ®Google Scholar
• HARA T, YOKOYAMA A, ISHIHARA H, YOKOYAMA Y, NA- GAHARA T, IWAMOTO M: DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor of factor Xa. Thromb. Haemost. (1994) 71 (3) :314–319.
   PubMed Web of Science ®Google Scholar
• •Biochemical analysis of Daiichi's fXa inhibitor.
   Google Scholar
• IKEDA Y, FUJITA M, MURAYAMA N et al.: Human phar-macokinetics, pharmacodynamics and tolerability of activated factor X inhibitor DX-9065a. Circulation (1998) 98 (17) :2389. Abstract.
   Google Scholar
• HARA T, YOKOYAMA A, TANABE K, ISHIHARA H, IWA-MOTO M: DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. (1995) 74 (2):635–639.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI M, ASAKURA H, AOSHIMA K et al. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Sem. Thromb. Hem ost. (1996) 22 (3) 255–259
   PubMed Web of Science ®Google Scholar
• TANIUCHI Y, SAKAI Y, HISAMICHI N et al: Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of hu-man factor Xa. Thromb. Haemost (1998) 79:543–548.
   PubMed Web of Science ®Google Scholar
• •Analysis of Yamanouchi's fXa inhibitor.
   Google Scholar
• TANIUCHI Y, SAKAI Y, KAWASAKI T eta].: Anticoagulant and pharmacokinetic profiles of YM-60828, an orally active and potent synthetic inhibitor of factor Xa. Thromb. Haemost. (1997) (Suppl. June):PS-1203. Abstract.
   Google Scholar
• KAWASAKI T, SATO K, SAKAI Y eta].: Comparative stud-ies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of ar-terial thrombosis. Thromb. Haemost. (1998) 79:410–416.
   Google Scholar
• SATO K, TANIUCHI Y, KAWASAKI T et al.: Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. Jpn. j Pharmacol. (1998) 78:191–197.
   PubMedGoogle Scholar
• SATO K, KAKU S, HIRAYAMA F et al: Antithrombotic ef-fect of YM-75466 is separated from its effect on bleed-ing time and coagulation time. Eur. J. Pharmacol (1998) 352:59–63.
   PubMed Web of Science ®Google Scholar
• PHILLIPS GB, BUCKMAN BO, DAVEY DD et al: Discoveryof /%4245-[Amino (imino) methy1]-2-hydroxyphenoxyl-3,5-difluoro-643- (4,5-dihydro- 1 -methyl-1 H-imidazol--2-y1) phenoxy] pyridin-4-y1]-/V-methylglycine (ZK-807834): A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J. Med. Chem. (1998) 41:3557–3562.
   PubMed Web of Science ®Google Scholar
• •Report on Berlex's fXa inhibitor.
   Google Scholar
• SUBRAMANYAM B, HO E, WALTERS J et al. The pharma- cokinetics of BX-807834 (BX), a potent, selective factor Xa inhibitor in animals. FASEB J (1998) 12(5) 4169 Ab-stract
   Google Scholar
• MORSER J: Efficacy and safety of BX-807834, a novel Xainhibitor. IBC's 9th Annual International Symposium on Advances in Anticoagulant, Antithrombotic and Throm-bolytic Drugs. Cambridge, MA, USA (1998).
   Google Scholar
• MADUSKUIE TP, MCNAMARA KJ, RU Y, KNABB RM, STOUTEN PFW: Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa in-hibitors. J. Med. Chem. (1998) 41:53–62.
   PubMed Web of Science ®Google Scholar
• •Report on DuPont's fXa inhibitor.
   Google Scholar
• PRUITT JR, PINTO DJ, QUAN ML et al.: Isoxazolines and isoxazoles as factor Xa inhibitors. Book of abstracts, 216th A CS National Meeting. Boston, USA (1998):MEDI077.
   Google Scholar
• PINTO DJ, ORWAT MJ, SHUAIGE W et al.: The discovery of a novel pyrazole SN429, a highly potent inhibitor of coagulation factor Xa. 217th ACS National Meeting. Ana-heim, CA, USA (1999):MEDI006
   Google Scholar
• MORGAN S, BENTLEY R, BOSTWICK J et al.: Pharmacody-namic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa. FASEB J (1998) 12(5):5531. (Abstract).
   Google Scholar
• COLUSSI D, BROWN K, BINA M et al: In vitro characteri-zation of a novel factor Xa inhibitor, RPR 120844. Blood (1998) 92(10) (Supp1.1):1489. Abstract.
   Google Scholar
• KLEIN SI, CZEKAJ M, GARDNER CJ et al.: Identificationand initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J. Med. Chem. (1998) 41:437–450.
   PubMed Web of Science ®Google Scholar
• HERAN C, MORGAN S, KASIEWSWKI C et al. Antithrom- botic efficacy of RPR208566 a factor Xa inhibitor in a rat model of carotid artery thrombosis. FASEB J (1998) 12 (5) 4153 Abstract
   Google Scholar
• GALEMMO RA, MADUSKUIE TP, DOMINGUEZ C eta].: Thede novo design and synthesis of cyclic urea inhibitors of factor Xa: Initial SAR studies: Bioorg. Med. Chem. Lett. (1998) 8:2705–2710.
   Google Scholar
• KAMATA K, KAWAMOTO H, HONMA T et al.: Structuralbasis for chemical inhibition of human blood coagula-tion factor Xa. Proc. Natl. Acad. Sci. USA (1998) 95:6630–6635.
   PubMed Web of Science ®Google Scholar
• •Crystallographic study of inhibitor bound to fXa.
   Google Scholar
• SCARBOROUGH RM: Coagulation factor Xa: the prothrombinase complex as an emerging therapeutic target for small molecule inhibitors. J. Enz. Inhib. (1998) 14:15–25.
   Google Scholar
• BETZ A, SINHA U: (In preparation).
   Google Scholar
• WONG AG, KU P, LIN PH et al: Inhibition of rabbit deepvein thrombosis by specific inhibitors of coagulation factor Xa. Thromb. Haemost. (1997) Suppl. June:PS-1197. Abstract.
   Google Scholar
• BENEDICT CR, TODD J, ZHU BY, SCARBOROUGH RM,SINHA U.: Factor Xa antagonist (C921-78) inhibits arte-rial thrombosis without impairment of extravascular hemostasis. Circulation (1997) 96 (8):220. Abstract.
   Google Scholar
• OSTREM JA, AL-OBEIDI F, SAFAR P et al.: Discovery of anovel, potent, and specific family of factor Xa inhibi-tors via combinatorial chemistry. Biochemistry (1998) 37:1053–1059.
   PubMed Web of Science ®Google Scholar
• •Biochemical analysis of Selectide's fXa inhibitor.
   Google Scholar
• OSTREM JA, STRINGER S, AL-OBEIDI F et al.: Characteri-zation of an orally available and highly specific syn-thetic factor Xa inhibitor. Thromb. Haemost (1995) 73 (6):1559. Abstract.
   Google Scholar
• MANN KG, NESHEIM ME, CHURCH WR, HALEY P, KRISHNASWAMY S: Surface - dependent reactions of the vitamin K - dependent enzyme complexes. Blood (1990) 76 (1)1–16.
   Google Scholar
• ••Review of mechanism of action of prothrombinasecomplex.
   Google Scholar
• SINHA U, HOLLENBACH S, WOLF DL: Macromolecularcomplex assembly of prothrombinase is a central pro-cess of thrombosis. Ann. NY Acad. Sci. (1994) 714:32–40.
   PubMed Web of Science ®Google Scholar
• HOLLENBACH S, SINHA U, LIN PH eta].: A comparativestudy of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein throm-bosis. Thromb. Haemost (1994) 71:357–362
   PubMed Web of Science ®Google Scholar
• KRISHNASWAMY S, BETZ A: Exosites determine macro- molecular substrate recognition by prothrombinase. Biochemistry (1997) 36:12080–12086.
   PubMed Web of Science ®Google Scholar
• •Details of exosite interaction.
   Google Scholar
• DUNWIDDIE CT, NEEPER MP, NUTT EM et al.: Site-directed analysis of the functional domains in the fac-tor Xa inhibitor tick anticoagulant peptide: Identifica-tion of two distinct regions that constitute the enzyme recognition sites. Biochemistry (1992) 31:12126–12131.
   PubMed Web of Science ®Google Scholar
• WET A, ALEXANDER RS, DUKE J, ROSS H, ROSENFELD SA,CHANG CH: Unexpected binding mode of tick antico-agulant peptide complexed to bovine factor Xa. J. Mol. Biol. (1998) 283:147–154.
   PubMed Web of Science ®Google Scholar
• THE MEDICAL RESEARCH COUNCIL'S GENERAL PRAC-TICE RESEARCH FRAMEWORK: Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet (1998) 351:233–241.
   PubMed Web of Science ®Google Scholar
• ••Report of a clinical trial of warfarin. The bibliography sec-tion includes several relevant references.
   Google Scholar